Aracoma Drug Company pleads guilty


By Owen Wells - [email protected]



In response to allegations of improprieties involving prescription drugs, the Aracoma Drug Company of Chapmanville has entered into a plea agreement with the acting U.S. attorney for the western district of Kentucky.

The plea agreement was filed Tuesday July 21 in U.S. district court in Kentucky and outlines the fact that, in order to allay possible penalties, Aracoma Drug agreed to waive indictment by a grand jury and instead plead guilty to a misdemeanor information (document outlining probable cause).

The plea agreement obtained by The Logan Banner lays out the facts of the case saying, “During the period of June 2009 through April 2012, Aracoma Drug Company of Chapmanville (“Aracoma”) operated a traditional and internet pharmacy located in the state of West Virginia which provided customers in Kentucky and several other states with prescription drugs. During the relevant period of the information, Aracoma electronically received invalid prescriptions…issued from questionnaires completed via the internet. These prescriptions were not issued following examinations…by a qualified medical provider….These prescriptions were then filled by Aracoma and subsequently shipped via commercial carrier….”

By entering the plea arrangement, Aracoma Drug could be subject to a $1,000 fine and a one year term of supervised release. However, Aracoma Drug also agreed to forfeit all profits that were derived from the illegal sale of prescription drugs by paying a $450,000 money judgement. Aracoma Drug must pay $100,000 at the time of sentencing in the case and $70,000 a year for the next five years.

http://loganbanner.com/wp-content/uploads/2015/07/web1_gavel1.jpg

By Owen Wells

[email protected]

Owen Wells is a reporter for Civitas Media. He can be reached at 304-752-6950 ext. 1729 or by email at [email protected]

Owen Wells is a reporter for Civitas Media. He can be reached at 304-752-6950 ext. 1729 or by email at [email protected]

comments powered by Disqus